Afternoon I: Within Country Biomarker Issues

- Sample collection protocols – feasibility, pros/cons, other issues?
  - DBS vs. Venous
  - Point-of-Contact
  - Other non-blood
    - Lung Fx
    - BP
    - BMI/WHR
    - Performance – e.g., cognitive and physical Fx
Afternoon I: Within Country Biomarker Issues

- Laboratories
  - Initiation evaluation (e.g., validation of assays)
  - On-going oversight - Quality control (over time)
- Sample storage (over time)
- Reporting issues – what information should/can be reported back to participants
  - Non-genetic
  - Genetic?
Harmonization Issues: Between Country Comparisons

- Equilibration between laboratories
  - NIH HIV centralized laboratory infrastructure (e.g., Hopkins and at NIH; big and $$$$$$)
  - Smaller scale options?
    - Centralized vs. decentralized?
    - Developing algorithms for cross-laboratory equilibration
      - Maintaining overtime?
Afternoon II: Group Discussion

- Session to lay-out the commonalities and unique issues faced by various of the different international studies – building on morning study-specific information – focusing here more on “issues” they face relating to biomarker data collection

- Recap from Perry’s talk
  - IFLS
  - CHARLS

- WISE/STAR - Duncan
- SHARE – Luzia/Karen
- SAGE – Somnath/Josh
- ELSA - Meena
- Others – TILDA, Scotland, Brazil?
Future Directions
“next steps”

- Priorities for coming year(s)?